Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 13/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12796678 | 0.79 | HTR7 (0.65) | HTR7HTR1AHTR2ADRD2SMN1; SMN2 | |
| SCHEMBL2297589 | 0.78 | HTR7 (0.64) | HTR7HTR1AHTR2ADRD2SMN1; SMN2 | |
| SCHEMBL27735646 | 0.72 | MEN1 (0.60) | HTR7HTR1AHTR2ADRD2MEN1 | |
| SCHEMBL2952863 | 0.72 | HTR7 (0.55) | HTR7HTR1AHTR2ADRD2SMN1; SMN2 | |
| SCHEMBL2952338 | 0.72 | HTR7 (0.60) | HTR7HTR1AHTR2ADRD2SMN1; SMN2 | |
| SCHEMBL13199785 | 0.72 | HTR7 (0.60) | HTR7HTR1AHTR2ADRD2 | |
| SCHEMBL9399130 | 0.69 | HSD17B10 (0.52) | HTR7HTR1AHTR2ADRD2MEN1 | |
| SCHEMBL15210977 | 0.68 | HTR7 (0.51) | HTR7HTR1AHTR2ADRD2MEN1 | |
| SCHEMBL6600143 | 0.68 | HTR7 (0.54) | HTR7HTR1AHTR2ADRD2 | |
| SCHEMBL5174350 | 0.68 | ALDH1A1 (0.61) | HTR7HTR1AHTR2ADRD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049090-B1 | USE OF 5-HT7 RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN | ESTEVE LABOR DR (ES) | 2011-10-05 | — | — | EP | disclosed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | disclosed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| WO-2010012811-A2 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-04 | — | — | WO | disclosed |
| US-20090326014-A1 | Use of 5-ht7 receptor agonists for the treatment of pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-12-31 | — | — | US | disclosed |
| WO-2008145335-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-04 | — | — | WO | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1875899-A1 | Use of 5HT7 receptor agonists for the treatment of pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | OPRL1, OPRM1, OPRK1 | HTR7 5/4885HTR1A 8/4885HTR2A 17/4885 |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | HTR7, HTR1A, HTR6 | HTR7 1/4885HTR1A 2/4885HTR2A 11/4885 |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | HTR7, HTR1A, HTR2C | HTR7 1/4885HTR1A 2/4885HTR2A 10/4885 |
| US-20090326014-A1 | Use of 5-ht7 receptor agonists for the treatment of pain | HTR7, HTR1A, OPRL1 | HTR7 1/4885HTR1A 2/4885HTR2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.